fda stance on compounded semaglutide Warns Against Using For Type 2 Diabetes, Weight Loss FDA says 'no clinical need'

& Zdravkovic, M

Highly experienced with GLP-1 receptor agonists

The choice between Semaglutide, Tirzepatide, and Retatrutide depends on factors like: Your weight loss goals Existing health conditions (e.g., Type 2 Diabetes) How your body responds to GLP-1 medications Your providers recommendations All three medications are highly effective, but Retatrutide may offer the most significant weight loss due to its triple-action mechanism

Always consult your GP as the first point of contact to explore what support is available to you

But heres the thing: There are no published clinical trials on GLP-1 microdosing in healthy adults

And now, were digging into the data to learn even more, so we can continue to expand access and make this process easier for everyone